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Abstract
Background: Patients with primary aldosteronism (PA) experience more cardiovas-
cular events compared to patients with essential hypertension (EHT), independent 
from blood pressure levels. In animals, mineralocorticoid receptor antagonists limit 
ischaemia‐reperfusion (IR) injury by increasing extracellular adenosine formation 
and adenosine receptor stimulation. Adenosine is an endogenous compound with 
profound cardiovascular protective effects. Firstly, we hypothesized that patients 
with PA have lower circulating adenosine levels which might contribute to the ob-
served increased cardiovascular risk. Secondly, we hypothesized that by this mecha-
nism, patients with PA are more susceptible to IR compared to patients with EHT.
Design: In our prospective study in 20 patients with PA and 20 patients with EHT, 
circulating adenosine was measured using a pharmacological blocker solution that 
halts adenosine metabolism after blood drawing. Brachial artery flow‐mediated dila-
tion (FMD) before and after forearm IR was used as a well‐established method to 
study IR injury.
Results: Patients with PA had a 33% lower adenosine level compared to patients 
with EHT (15.3 [13.3‐20.4] vs 22.7 [19.4‐36.8] nmol/L, respectively, P < .01). The 
reduction in FMD after IR, however, did not differ between patients with PA and 
patients with EHT (−1.0 ± 2.9% vs −1.6 ± 1.6%, respectively, P = .52).
Conclusions: As adenosine receptor stimulation induces various powerful protec-
tive cardiovascular effects, its lower concentration in patients with PA might be 
an important novel mechanism that contributes to their increased cardiovascular 
risk. We suggest that modulation of the adenosine metabolism is an exciting novel 
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1 |  INTRODUCTION
Primary aldosteronism (PA) is the most common cause of 
secondary hypertension, with an estimated prevalence of 
10% in the hypertensive population.1 Importantly, patients 
with PA experience more cardiovascular events, including 
stroke and myocardial infarction, compared to patients with 
essential hypertension (EHT), independent from the blood 
pressure level.2 Also, in patients without PA, a high plasma 
aldosterone level is associated with an increased risk of car-
diovascular events.3 In patients with heart failure, plasma al-
dosterone is increased and treatment with mineralocorticoid 
receptor (MR) antagonists improves outcome.4,5 These ob-
servations suggest that aldosterone has direct adverse cardio-
vascular effect, over and above the detrimental effect of blood 
pressure elevation.
Indeed, preclinical studies have shown that aldoste-
rone has direct adverse cardiovascular effects: aldosterone 
increases atherosclerosis and promotes plaque formation 
via the MR,6,7 aldosterone reduces coronary blood flow,8 
it stimulates vascular and myocardial fibrosis9-11 and vas-
cular inflammation,12,13 and aldosterone increases infarct 
size in animal models of myocardial infarction,14 although 
this latter result has not been reported in other studies.15,16 
In addition, the administration of MR antagonists consis-
tently reduces myocardial infarct size in these animal mod-
els.17Schmidt et al15 recently proposed that the endogenous 
nucleoside adenosine might be involved in these detrimental 
effects, by showing that the cardioprotective effects of MR 
antagonists are fully dependent on adenosine receptor signal-
ling. Adenosine is formed by intracellular and extracellular 
degradation of adenosine monophosphate by the enzyme 
ecto‐5’‐nucleotidase (CD73). Stimulation of membrane‐
bound adenosine receptors induces various protective effects, 
including vasodilation, inhibition of inflammation and fibro-
sis, prevention of atherosclerosis and protection against IR 
injury.18 Endogenous adenosine is considered a “retaliatory 
metabolite”, which protects the cardiovascular system in sit-
uations of impending danger, and acts as a key mediator of 
the infarct size‐limiting effect of several pharmacological and 
nonpharmacological strategies.18
Firstly, we hypothesized that patients with PA have lower 
adenosine levels and that this contributes to their increased 
cardiovascular risk compared to patients with EHT. Secondly, 
we hypothesized that a lower adenosine concentration is 
associated with increased susceptibility to IR. We measured 
circulating adenosine concentrations and the activity of the 
main adenosine‐producing enzyme CD73 on isolated mono-
nuclear cells. To study IR in humans in vivo, a safe and well‐
validated method is examining brachial artery flow‐mediated 
dilation (FMD) before and after forearm IR.19 This protocol 
of IR results in an immediate decrease in brachial artery 
FMD, which reflects IR‐induced endothelial dysfunction.20,21
2 |  DESIGN
We performed a prospective case‐control study including 
patients with PA and patients with EHT from two centres 
in the Netherlands from October 2013 to March 2017. All 
patients with PA were recruited in the Radboud university 
medical center, which serves as a tertiary referral centre for 
PA in the Netherlands. The diagnosis of PA is made accord-
ing to the current international guideline, by aldosterone and 
renin measurement, followed by a confirmation test.22 For 
the inclusion of control patients with EHT, we asked patients 
from the outpatient clinic of the Radboud university medical 
center and the Rijnstate Hospital, Arnhem, The Netherlands.
All volunteers were 18‐75 years of age and provided writ-
ten informed consent. Exclusion criteria were as follows: a 
history of atherosclerotic disease, cardiac failure, diabetes 
mellitus or severe renal dysfunction (MDRD < 30 mL/min), 
current smoking, a 2nd or 3rd degree atrioventricular block 
on electrocardiography and the usage of drugs that influence 
adenosine formation: nonsteroidal anti‐inflammatory drugs, 
theophylline or dipyridamole. An overview of the patient se-
lection and inclusion process is depicted in Figure 1.
The study was approved by the Institutional Review Board 
of our centre and conducted in accordance with Good Clinical 
Practices and the Declaration of Helsinki. We prospectively 
registered our study at ClinicalTrials.gov by number NCT 
01978132. Reporting of the study conforms to STROBE 
statement along with references to STROBE statement and 
the broader EQUATOR guidelines.23
2.1 | Diagnosis of PA and EHT
Concordant with the guideline of the Endocrine society, no 
antihypertensive drugs other than calcium channel block-
ers, doxazosin and/or hydralazin were taken in the 4 (for 
pharmacological opportunity to limit cardiovascular risk in patients with PA that 
needs further exploration.
K E Y W O R D S
adenosine, aldosterone, hypertension, ischaemia‐reperfusion injury, primary aldosteronism
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spironolactone, eplerenone, amiloride, triamterene or 
aliskiren) or 2 (for all other antihypertensive drugs) weeks 
prior to aldosterone and renin measurements.22
In the Radboud university medical center, plasma active 
renin concentration was measured by an immunoradiometric 
assay (RENIN III generation, CIS Bio International). Serum 
aldosterone concentration was measured after extraction and 
paper chromatography with recovery correction, as described 
earlier.24 In patients from the Rijnstate Hospital, plasma al-
dosterone and plasma renin activity were measured by radio-
immunoassays (Labor Stein, Mönchengladbach, Germany, 
and IJsselland Hospital, Capelle a/d IJssel, The Netherlands, 
respectively).
Patients with PA had a baseline aldosterone level of 
>0.42 nmol/L and ARR level of >0.09 nmol/mU. In all pa-
tients with PA, the diagnosis was confirmed by a salt loading 
test (aldosterone concentration >0.28 nmol/L after infusion 
of 2 L of saline in 4 hours). Patients with confirmed PA un-
derwent sequential adrenal venous sampling of the right and 
left adrenal vein during cosyntropin infusion to assess uni‐ or 
bilateral aldosterone overproduction. Criteria for a unilat-
eral aldosterone overproduction were met when the left vs 
right (or vice versa) aldosterone‐cortisol ratio was ≥4.0 and 
the ratio of the contralateral site was ≤1.0, as an indication 
for contralateral suppression. Of the patients with unilateral 
aldosterone overproduction who underwent adrenalectomy, 
we screened the pathology reports.
In all patients with EHT, PA was excluded by a baseline 
aldosterone concentration of <0.42 nmol/L and ARR value 
of <0.09 nmol/mU or <0.65 nmol/L per ng/mL/h
2.2 | Experimental design
We performed the experiments shortly after the diagno-
sis of PA was confirmed. Upon screening, most patients 
with EHT used various antihypertensive drugs. In both pa-
tients with PA and EHT, we changed the antihypertensive 
medication into diltiazem, with or without doxazosine or 
hydralazin, to minimize variation in medication and to ex-
clude effects on the experiments.25 At least 1  week after 
the change in medication, we draw blood to determine the 
adenosine concentration and performed the FMD experi-
ment (see below). Since statins are known to upregulate 
CD73, these drugs had to be temporarily withdrawn during 
at least 1 week before the experiments.26 In addition, we 
aimed to avoid hypokalaemia during the FMD experiment 
by potassium suppletion, if needed.
On the experimental day, patients took their medication, 
except for potassium suppletion, after brachial FMD measure-
ment, to avoid interference of these drugs in FMD assessment.27
F I G U R E  1  Overview of the selection 
process of patients. Abbreviations: EHT, 
essential hypertension; FMD, flow‐mediated 
dilation; IR, ischaemia reperfusion; and PA, 
primary aldosteronism
Assessed for eligibility (n = 216) 
patients with PA (n = 141) 
patients with EHT (n = 75) 
Not eligible (n = 176) 
not meeting inclusion criteria (n = 77) 
declined to participate (n = 36) 
diagnosis uncertain (based on ARR or 
salt loading test) (n = 14) 
unable to switch drugs (n = 30) 
other reasons (n = 19) 
Analysis of FMD (n = 19) 
Analysis of circulating adenosine (n = 14) 
excluded from analysis (FMD and adenosine) 
due to a caffeine level >1 mg/L (n = 1) 
FMD (n = 20) and adenosine measurement 
(n = 15) 
technical failure in adenosine 
measurement (n = 2) 
unfeasible to draw blood using the 
purpose-built syringe (n = 3) 
Patients with PA (n = 20) 
FMD (n = 19) and adenosine 
measurement (n = 17) 
drop out due to intolerance to diltiazem 
(n = 1) 
no post-IR FMD due to adverse event (n = 1) 
unfeasible to draw blood using the purpose-
built syringe (n = 2)
Patients with EHT (n = 20) 
Analysis FMD (n = 19) 
no post-IR, but pre-IR only (n = 1) 
Analysis of circulating adenosine (n = 17) 
Inclusion 
Analysis 
Experiment 
Enrollment 
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2.3 | Circulating adenosine concentration
It is notoriously difficult to measure circulating adenosine, be-
cause of the extremely short half‐life, necessitating immediate 
pharmacological blockade of adenosine metabolism as soon as 
blood is withdrawn. We used a state‐of‐the‐art technique, which 
we validated previously.28 Using a purpose‐built syringe, the 
blood mixes immediately at the end of the needle with a solution 
containing pharmacological blockers of the proteins involved in 
adenosine formation, transport and degradation.
In more detail, we drew 2.5  mL of blood before the 
start of the experiment that was immediately mixed with a 
2.5 mL solution containing 40 μmol/L dipyridamole (Sigma), 
10  μmol/L erythro‐9‐(2‐hydroxy‐3‐nonyl) adenine hydro-
chloride (Sigma), 10  μmol/L 5‐iodotubercidin (Biomol), 
11.5  µmol/L forskolin (Fluka) and 115  µmol/L IBMX 
(Sigma), buffered in 13.2  mmol/L Na2EDTA, 118  mmol/L 
NaCl and 5 mmol/L KCl; pH 7.4.
The hemocrit of this solution was measured in order to 
correct for dilution. We directly centrifugated the blood 
mixed with blockers for 10 minutes at 1000 g, at 4°C. The 
plasma was then stored at −80°C until analysis.
After derivatization with chloroacetaldehyde, the formed 
1,N6‐ethenoadenosine concentration was analysed using re-
versed‐phase high‐performance liquid chromatography and flu-
orescence detection with excitation and emission wavelength set 
at 280 and 420 nm. Separation took place on a Polaris column 
(Varian, Polaris 3 µm C18‐A 150 × 4.6 mm) with a mobile phase 
containing 50 mmol/L NH4H2PO4 5 mmol/L of hexane sulphonic 
acid (pH 3.0). Acetonitrile was used as the organic modifier.
2.4 | CD73 activity on mononuclear cells
Before start of the FMD experiment, we drew blood for the iso-
lation of mononuclear cells. We used Cell Preparation Tubes 
(CPT 8  mL, BD Vacutainer) for the separation of mononu-
clear cells from whole blood. Within 2 hours after blood col-
lection, we centrifuged the tubes for 20 minutes at 1600 g, at 
20°C without brake. We transferred the layer of mononuclear 
cells and washed the cells twice using phosphate‐buffered saline 
(137 mmol/L NaCl, 2.7 mmol/L KCl, 10 mmol/L Na2HPO4 and 
1.8 mmol/L KH2PO4; pH 7.4). Subsequently, we resuspended 
the mononuclear cells in 0.5 mL Hank's balanced salt solution 
(HBSS, Gibco by Life Technologies) at room temperature. We 
determined the activity of CD73 exposed on the surface of these 
intact mononuclear cells measuring the conversion of 1,N6‐ethe-
noadenosine 5′‐monophosphate to 1,N6‐ethenoadenosine with 
HPLC, as previously described.26
2.5 | Additional blood drawing
Before start of the experiment we drew blood to determine 
plasma potassium levels and caffeine concentrations, as 
described previously.29 Subjects with a circulating caffeine 
concentration >1.0 mg/L were excluded from analysis, since 
caffeine is a potent adenosine receptor antagonist.30
2.6 | Flow‐mediated dilation (FMD)
All FMD experiments were performed in the morning, after 
an overnight fast and after 24 hours of alcohol and caffeine 
abstinence.
We measured the brachial blood pressure in the supine 
position using a manual sphygmomanometer, in a quiet room 
after a period of 5 minutes rest. We measured the blood pres-
sure 3 times and reported the mean of the second and third 
blood pressure measurement.
An experienced sonographer, who was blinded for the 
diagnosis, examined brachial FMD in a darkened, tempera-
ture‐controlled room of 22.3 ± 0.5°C, after a minimum time 
of rest of 15 minutes after venipuncture. We used a 10‐MHz 
multifrequency linear‐array probe attached to a high‐resolu-
tion ultrasound machine (Terason T3000), according to the 
guideline of Thijssen et al.27
The patients rested in a supine position with both arms 
extended and immobilized, supported at an angle of ~80° 
abduction from the torso. For the assessment of FMD, we 
positioned a rapid inflation/deflation pneumatic cuff distal to 
the olecranon process to provide an ischaemic stimulus dis-
tal from the brachial artery, leading to reactive hyperaemia 
and subsequent shear stress. We imaged the brachial artery 
in the distal third of the upper arm. We recorded baseline 
diameter and blood flow velocity during 1 minute. This was 
followed by inflation of a pneumatic cuff around the fore-
arm for 5 minutes to a pressure of 200 mm Hg. We captured 
changes in brachial artery diameter, blood flow velocity and 
shear rate 30  seconds before cuff deflation until 3 minutes 
post‐deflation continuously.
For the assessment of endothelial IR injury, we posi-
tioned the rapid inflation/deflation cuff around the upper 
arm and inflated the cuff to a pressure of 200 mm Hg (or 
50  mm  Hg above systolic blood pressure [SBP]) during 
20  minutes, followed by 20  minutes of reperfusion. After 
this period of IR, we repeated the FMD measurements as 
described above.
Analysis of the brachial artery diameter was performed 
offline, in a blinded fashion, using custom‐designed edge‐
detection and wall‐tracking software, which is indepen-
dent of investigator bias.31 Baseline data were calculated 
across the 1 minute preceding cuff inflation. We used the 
automatically detected peak diameter after cuff deflation 
to express the FMD as the % change in diameter ([peak di-
ameter after deflation − baseline diameter]/baseline diam-
eter × 100%). Other outcome measures that were assessed 
include time to peak (sec) and shear rate (area under the 
curve).
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2.7 | Statistical analysis
In a recent study with a similar experimental design, we 
observed a reduction in FMD by forearm IR injury from 
6.4% to 4.4%.32 The average reduction in FMD by IR was 
2.0% (standard deviation [SD] 2.4%). To demonstrate a 
twofold increase in IR damage with an alpha of 0.1 and a 
power of 80%, a sample size of 18 patients per group was 
required. To account for drop outs, we included 20 patients 
in both groups.
We used ibm spss Statistics 22 for the analysis of the 
data. We expressed normally distributed variables as 
mean ± SD and non‐normally distributed variables as me-
dian (interquartile range). The baseline characteristics were 
compared using an independent t test for normally distrib-
uted values and a Mann‐Whitney test for non‐normally 
  PA (n = 20) EHT (n = 20) P‐value
Demographics
Male (%) 12 (60) 13 (65) 1.00
Mean age (SD) 50.9 (12.2) 48.4 (14.6) .21
Screening
Mean SBP (SD) 155 (19) 155 (25) 1.00
Mean DBP (SD) 91 (14) 91 (12) .88
Mean heart rate (SD) 71 (17) 70 (13) .86
Median duration of known 
hypertension in years (IQR)
7.5 (2.6‐12.5) 6.0 (4.0‐11.5) .84
Median baseline aldosterone 
in nmol/L (IQR)
0.81 (0.61‐0.93) 0.22 (0.11‐0.28) <.01
Median baseline ARR in 
nmol/mU (IQR) (n = 15)
0.22 (0.17‐0.25) 0.01 (0.01‐0.02) <.01
Median baseline ARR in 
nmol/L per ng/mL/h (IQR) 
(n = 5)
– 0.41 (0.15‐0.49) –
Mean plasma sodium in 
mmol/L (SD)
141.9 (2.7) 141.0 (1.7) .14
Median plasma potassium 
(IQR)
3.8 (3.6‐4.0) 4.0 (3.8‐4.1) .03
Median plasma creatinine in 
µmol/L (IQR)
75.0 (68.0‐84.0) 84.5 (71.5‐89.5) .13
Median kidney function 
(MDRD) in mL/min (IQR)
84 (76‐91) 79 (75‐91) .57
Mean total plasma cholesterol 
in mmol/L (nonfasting) (SD)
5.2 (1.0)
n = 19* 
4.9 (1.0)
n = 19* 
.33
Median plasma glucose in 
mmol/L (nonfasting) (IQR)
5.3 (4.9‐5.9)
n = 20
5.2 (4.8‐5.8)
n = 18† 
.59
Risk factors
History of smoking (%) 8 (40) 10 (50) .75
Median units of alcohol per 
week (IQR)
3.5 (0‐7.0) 2.0 (0‐10.0) .67
Mean BMI (SD) 27.5 (5.6) 27.4 (4.3) .96
Dyslipidaemia (%) 4 (20) 6 (30) .72
1st grade family history of 
hypertension or CVD (%)
12 (60) 16 (80) .30
Abbreviations: ARR, aldosterone‐to‐renin ratio; BMI, body mass index; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; EHT, essential hypertension; IQR, interquartile range; MDRD, modification of diet 
in renal disease; PA, primary aldosteronism, PY, pack years; SBP, systolic blood pressure; and SD, standard 
deviation.
*in 1 patient a value of a fasting (vs nonfasting) cholesterol was available. 
†in 2 patients a value of a fasting (vs nonfasting) glucose value was available. 
T A B L E  1  Baseline characteristics
6 of 11 |   BERG Et al.
distributed variables. We assessed differences between pro-
portions with the Pearson chi‐square test or Fisher's exact 
for smaller proportions. We assumed a significance level 
of ≤0.05.
3 |  RESULTS
3.1 | Patients
We included 5 patients with EHT from the Rijnstate Hospital. 
All other patients (20 patients with PA and 15 patients with 
EHT) were recruited from the Radboud university medical 
center.
As expected, baseline aldosterone, ARR and plasma po-
tassium levels differed significantly between patients with 
PA and patients with EHT. There were no differences regard-
ing other baseline characteristics (Table 1).
Of the 20 patients with PA, 13 patients had unilateral al-
dosterone overproduction and 7 patients had bilateral aldoste-
rone overproduction.
One patient with EHT dropped out because of intolerance 
to diltiazem. In one patient with EHT we ended the experi-
ment during the period of upper arm ischaemia, because of 
sudden appearance of petechiae of the ischaemic arm. Most 
likely this was caused by a rise in SBP during upper arm 
occlusion, leading to venous congestion in the arm. During 
follow up, this patient recovered without any symptoms or 
complaints. We had to exclude one patient with PA from 
the analysis, because of a circulating caffeine concentration 
>1.0 mg/L.
On the experimental day, blood pressure and the daily de-
fined dosage of antihypertensive drugs did not differ between 
patients with PA and patients with EHT (Table 2). Among 
the 19 patients with PA, there was no need for antihyperten-
sive therapy in 6 patients. Eleven patients used diltiazem, one 
patient used diltiazem plus doxazosin and one patient used 
diltiazem, doxazosin and hydralazin. Of the 19 patients with 
EHT, 9 patients did not use any antihypertensive drug before 
FMD measurement, 8 patients used diltiazem only and 2 pa-
tients used diltiazem plus doxazosin.
Despite the usage of potassium suppletion in 17 of 19 pa-
tients with PA, plasma potassium values were slightly lower 
than in patients with EHT (Table 2).
3.2 | Circulating adenosine levels
Levels of circulating adenosine were measured in 17 patients 
with EHT (11 male) and 14 patients with PA (9 male). Next 
to the earlier mentioned 2 drop outs, we were not able to draw 
blood using the purpose‐built syringe in n  =  5. In 2 other 
patients, we did not obtain a circulating adenosine concentra-
tion due to technical failures.
The sex distribution, age and blood pressure did not differ 
significantly between the 14 patients with PA and 17 patients 
with EHT (data not shown).
As depicted in Figure 2, the concentration of circulating 
adenosine was 15.3 (13.3‐20.4) nmol/L in patients with PA 
and 22.7 (19.4‐36.8) nmol/L in patients with EHT (P = .008).
3.3 | CD73 activity
There was no significant difference in CD73 activity of intact 
mononuclear cells of patients with PA vs patients with EHT. 
Patients with PA had a CD73 activity of 0.43 (0.19‐0.55) vs 
0.54 (0.33‐0.80) nmol/min per mg protein in patients with 
EHT; P = .21.
  PA (n = 19) EHT (n = 19) P‐value
Mean potassium value in mmol/L 
(SD)* 
3.5 (0.3) 3.9 (0.4) <.01
Mean SBP in mm Hg (SD) 158 (19) 155 (21) .66
Mean DBP in mm Hg (SD) 96 (9) 93 (10) .37
Median heart rate in x/min (IQR) 64 (60‐68) 60 (60‐68) .47
Median number of antihypertensive 
drugs (IQR)
1 (0‐1) 1 (0‐1) .31
Median DDD antihypertensive drugs 
(IQR)
0.83 (0.00‐1.00) 0.75 (0.00‐0.83) .20
Mean duration in min between reper-
fusion and post‐FMD measurement 
(SD)† 
21.7 (1.9) 22.7 (2.7) .20
Abbreviations: DBP, diastolic blood pressure; DDD, daily defined dosage; EHT, essential hypertension; FMD, 
flow‐mediated dilation; IQR, interquartile range; IR, ischaemia reperfusion; PA, primary aldosteronism; SBP, 
systolic blood pressure; and SD, standard deviation.
*n = 18 in both patient groups. 
†No post‐IR FMD measurement is available in 1 patient with EHT. 
T A B L E  2  Clinical parameters at the 
moment of FMD measurement
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3.4 | FMD measurement
Brachial artery characteristics before and after IR are shown 
in Table 3. FMD (peak diameter after cuff deflation), the % 
FMD, time to peak and shear rate did not differ significantly 
between patients with PA and patients with EHT before 
and after IR. In patients with EHT, % FMD decreased sig-
nificantly after IR (4.9 ± 1.9 to 3.3 ± 2.0%, P = .001). The 
decrease in % FMD was not significant within the group of 
patients with PA (4.4 ± 2.1 to 3.3 ± 2.7, P = .14).
Post‐IR % FMD minus pre‐IR % FMD did not differ be-
tween patients with PA and patients with EHT (−1.0 ± 2.9% 
vs −1.6 ± 1.6% respectively, P = .52).
4 |  DISCUSSION
In the present study, we show for the first time that patients 
with PA have lower levels of circulating adenosine compared 
to patients with EHT. Since adenosine has potent cardiovas-
cular protective properties, this mechanism could, at least 
in part, contribute to the increased risk of cardiovascular 
complications in patients with PA compared to patients 
with EHT and might offer novel potential targets for drug 
treatment.
Adenosine is an endogenous purine nucleoside with sev-
eral beneficial effects on the cardiovascular system, includ-
ing vasodilation, anti‐atherosclerotic effects, inhibition of 
inflammation and fibrosis, and limitation of IR injury.33 The 
importance of these effects is highlighted by previous studies 
reporting that genetic variants in the adenosine metabolism 
leading to increased endogenous adenosine formation im-
prove cardiovascular survival in patients with coronary artery 
disease.34
Given these beneficial effects of adenosine receptor stim-
ulation, it is logical to assume that a reduction in circulat-
ing adenosine impairs cardiovascular function. In line with 
this, we previously reported that patients with severe hy-
perhomocysteinaemia, in whom the risk of cardiovascular 
events is strongly increased, adenosine‐induced vasodilation 
is impaired due to an increased uptake of adenosine into 
the intracellular compartment, limiting adenosine receptor 
stimulation.35
In our study, we have now shown that also in patients 
with PA the endogenous adenosine concentration is reduced. 
Although aldosterone might have multiple potentially ad-
verse cardiovascular effects that are independent from lower-
ing aldosterone, we propose that modulation of the adenosine 
metabolism might prove to be an exciting and novel phar-
macological approach to reduce the excess risk of cardiovas-
cular events in patients with PA. We previously showed that 
treatment with MR antagonists does not increase extracel-
lular adenosine formation in healthy humans in vivo.36 It is 
of great interest to explore the effects of drugs known to in-
crease extracellular adenosine levels, including dipyridamole 
or statins, in patients with PA.37,38
The circulating concentration of adenosine is the sum 
of adenosine production, cellular uptake and intracellular 
degradation. Activity of the enzyme CD73, which cataly-
ses the extracellular formation of adenosine from adenosine 
F I G U R E  2  Circulating adenosine concentrations in nmol/L in 
patients with primary aldosteronism (PA; n = 14) and patients with 
essential hypertension (EHT; n = 17)
T A B L E  3  Brachial artery characteristics before and after IR
 
Pre‐IR Post‐IR P‐values
PA (n = 19) EHT (n = 19) PA (n = 19) EHT (n = 18)* Pre‐IR Post‐IR
Mean brachial artery diameters 
in mm (SD)
0.422 (0.074) 0.418 (0.084) 0.469 (0.084) 0.431 (0.081) .86 .18
Mean FMD in mm (SD) 0.441 (0.076) 0.437 (0.083) 0.483 (0.081) 0.445 (0.080) .90 .16
Mean FMD in % (SD) 4.4 (2.1) 4.9 (1.9) 3.3 (2.3) 3.3 (2.0) .47 1.00
Median time to peak in sec 
(IQR)
54 (38‐89) 50 (40‐74) 63 (32‐75) 50 (31‐77) .58 .73
Mean shear rate AUC (SD) 21945 (10103) 19968 (8572) 17623 (11737) 19293 (11910) .52 .67
Abbreviations: AUC, area under the curve; EHT, essential hypertension; FMD, flow‐mediated dilation; IQR, interquartile range; IR, ischaemia reperfusion; PA, pri-
mary aldosteronism; and SD, standard deviation.
*No post‐IR FMD measurement is available in 1 patient with EHT. 
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monophosphate, did not differ between the patients with 
PA and EHT. Therefore, increased cellular uptake and deg-
radation of adenosine most probably explains the lower 
adenosine concentration, comparable to patients with hy-
perhomocysteinaemia.35 Future studies should focus on 
unravelling the metabolic changes driving lower adenos-
ine levels, to be able to predict how these levels can be in-
creased pharmacologically.
Since adenosine is known to limit IR injury, we hypoth-
esized that the susceptibility to IR is higher in patients with 
PA. However, in our study, lower levels of circulating ade-
nosine were not associated with increased susceptibility to 
endothelial IR. There are several potential explanations for 
this discrepant finding. Firstly, the beneficial effect of ade-
nosine on IR injury is controversial, at least in humans in 
vivo. Whilst administration of adenosine before reperfusion 
diminished IS in patients with an anterior wall MI,39,40 sev-
eral preclinical studies41-43 and clinical studies44,45 failed 
to show an effect of exogenous adenosine on IR injury. 
Secondly, even if enhanced adenosine receptor stimulation 
might limit IR injury, this does not necessarily mean that a 
reduction in adenosine receptor stimulation would augment 
IR injury. For example, adenosine receptor antagonists did 
not increase infarct size itself in preclinical models of IR in-
jury,15 although these antagonists did significantly prevent 
the beneficial effects of ischaemic pre‐conditioning and post‐
conditioning.46,47 Thirdly, many endogenous substances and 
underlying mechanisms other than the adenosine metabolism 
regulate IR susceptibility, including an increase in reactive 
oxygen species, a decrease in intracellular pH and a reduction 
in bioavailability of nitric oxide.48
Future studies in patients with PA should therefore not 
focus on IR injury, but on alternative determinants of cardio-
vascular damage.
One of the processes that might be affected by adenosine 
in the context of PA is atherosclerosis. First, patients with 
PA have an increased risk of atherosclerotic complications, 
including myocardial infarction and stroke, compared to 
patients with EHT.2 Second, in animal models aldosterone 
increases atherosclerosis and promotes plaque formation via 
the MR.6,7 Third, adenosine has anti‐atherosclerotic proper-
ties18 and in genetic deletion models, inactivation of the ade-
nosine metabolism leads to progression of atherosclerosis.49
Similarly, fibrosis and inflammation might be the link be-
tween the reduced concentration of circulating adenosine in 
patients with PA and their increased risk of cardiovascular 
events. In preclinical studies, aldosterone stimulates vascular 
and myocardial inflammation and fibrosis and hence plays 
an important pathophysiological role in remodelling of the 
heart and vessel wall.9-13 Since adenosine has anti‐fibrotic 
and anti‐inflammatory properties,18 the reduced levels of cir-
culating adenosine in patients with PA compared to patients 
with EHT might contribute to the increased prevalence of 
cardiovascular morbidity and mortality in general in patients 
with PA compared to patients with EHT.
We therefore propose that the reduced circulating adenos-
ine levels in patients with PA may contribute to progression 
of atherosclerosis or fibrosis and inflammation, rather than 
IR injury. Our study benefits from the use of stringent criteria 
for the diagnosis of PA and EHT, detailed clinical charac-
terization of the patients, and much care to avoid the use of 
interfering antihypertensive and cholesterol‐lowering drugs. 
In addition, having a long tradition in human in vivo research 
on adenosine, we used optimal and well‐validated methods 
to detect circulating adenosine. Finally, FMD was measured 
according to expert consensus guidelines that were developed 
by one of the authors.27
Nevertheless, some aspects of our methods and results 
merit critical discussion. First, although some patients 
dropped out of the study, the group size was according to the 
sample size calculation with regard to measuring IR injury. 
Circulating adenosine concentrations could be measured in 
14 patients with PA and 17 patients with EHT, due to diffi-
culties in the sample collection or processing of the samples. 
Nevertheless, the difference in the adenosine concentrations 
was statistically significant (P = .008).
Secondly, we studied endothelial IR injury in the forearm 
vasculature and not directly in myocardial tissue. Despite im-
portant differences between brachial and coronary arteries, 
however, brachial FMD accurately reflects coronary endo-
thelial function,27,50 and brachial FMD is a good predictor of 
future cardiovascular events.51 The reduction in FMD imme-
diately after a period of forearm ischaemia has been well‐val-
idated in the literature to reflect endothelial IR injury, which 
can be prevented by strategies that are known to also limit 
histological myocardial infarct size in animal models.19,52
Thirdly, we did not observe a difference in baseline FMD 
between patients with PA and patients with EHT. This is in 
contrast to previous clinical studies in these patients.53-55 
Several explanations can be found for the discrepancies be-
tween our study and these studies. In contrast to the study 
of Nishizaka et al,53 we used stringent diagnostic criteria 
for PA and EHT, concordant to international guidelines. 
Importantly, we standardized antihypertensive treatment to 
diltiazem with or without hydralazin and/or doxazosin. In 
previous studies,53-55 different antihypertensive drugs may 
have modulated endothelial function, and therefore, their re-
sults have to be interpreted with caution.56 Furthermore, the 
above mentioned studies do not describe any dietary restric-
tions before FMD measurement.53-55 In our study, patients 
were 24 hours free of alcohol and caffeine before FMD mea-
surement, as recommended in the expert guideline.27 Next, 
we excluded patients with an history of cardiac failure, ath-
erosclerotic disease, severe renal dysfunction, diabetes mel-
litus and/or current smoking. Chou et al55 do not describe 
any of these baseline characteristics. It is therefore unclear 
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whether the presence of co‐morbidities may have led to the 
observed difference in baseline FMD between patients with 
PA and EHT.55 Finally, in the study by Matsumoto et al,54 a 
reduction in % FMD was seen only in those patients with PA 
who suffered from aldosterone‐producing adenomas, and not 
idiopathic aldosteronism. Likewise, of the 35 patients with 
PA in the study by Chou et al,55 91% had an aldosterone‐
producing adenoma. The percentage of patients with a his-
tologically proven unilateral aldosterone‐producing adenoma 
in our study was smaller, namely 53%. Nevertheless, we did 
not observe differences in baseline FMD between the patients 
with unilateral aldosterone‐producing adenoma and bilateral 
aldosterone overproduction (4.8 ± 1.9% vs 4.3 ± 2.5% respec-
tively; P = .67). Interestingly, we did observe a trend towards 
an increased susceptibility to IR in the subset of patients with 
a unilateral aldosterone‐producing adenoma. FMD decreased 
from 4.8 ± 1.9% to 2.6 ± 2.2% in patients with a histolog-
ically proven unilateral producing adenoma compared to 
4.3 ± 2.5% to 3.8 ± 1.7 in patients with bilateral aldosterone 
overproduction; P  =  .13. Circulating adenosine concentra-
tions did not differ between the patients with a histologically 
proven unilateral producing adenoma and the patients with 
bilateral aldosterone overproduction (data not shown).
In conclusion, patients with PA have lower levels of cir-
culating adenosine compared to patients with similar blood 
pressure levels due to EHT. This mechanism provides a 
novel and exciting explanation for the increased risk of 
cardiovascular events in patients with PA, compared to pa-
tients with EHT. Drugs beneficially affecting the adenosine 
metabolism could therefore potentially reduce the risk of 
future cardiovascular events in patients with PA. However, 
the adverse cardiovascular effects of aldosterone probably 
involve multiple pathways, and the effects of increasing ad-
enosine remains to be tested.
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